NAD+ Reconstitution Calculator
NAD+ has published human dosing figures, and almost none of them belong to the thing people inject. The record behind this page holds two: an intravenous dose of NAD+ itself, from a randomised trial in ischaemic cardiomyopathy, and a span of oral doses of nicotinamide mononucleotide (NMN), a precursor the body salvages into NAD+ inside the cell. No published human trial here has studied subcutaneous NAD+ at any dose, which is the form compounding pharmacies and wellness clinics sell. Published figures in this record cover intravenous and oral administration only; nothing in it covers intramuscular or intranasal NAD+. NR, NMN and NAD+ are three distinct molecules and their doses are not interconvertible. The calculator below converts a vial size and a mixing volume into mg/ml and U-100 syringe units. That is arithmetic about a vial, not a recommendation about what to inject.
Curated by Dosavy from published literature and regulator labels. Published 11 September 2026, last reviewed 11 September 2026. No clinician reviews this page.
Enter a target dose above to see the draw.
What the evidence says
| Experience | Route | Range | Frequency |
|---|---|---|---|
| Intermediate | Intravenous | 10 mg[1]NAD+ itself, administered intravenously. The single largest randomised trial of NAD+ (not a precursor) in this corpus: 180 adults with ischemic cardiomyopathy, LVEF <=45%, NYHA II-III, randomised to intravenous NAD+ 10 mg/day or placebo (5% glucose/normal saline) for 7 days alongside guideline-directed therapy, with change in LVEF at 1 month as the primary endpoint. Two things follow. First, this is a 7-day inpatient course in heart failure, not a wellness protocol. Second, 10 mg/day is one to two orders of magnitude below the 500-1000 mg intravenous doses sold as NAD+ infusions, a gap the community figures do not acknowledge. | Once daily by intravenous infusion for 7 days |
| Intermediate | Oral | 250–2000 mg[2][3][4]THIS IS A DOSE OF beta-NICOTINAMIDE MONONUCLEOTIDE (NMN), a precursor, not of NAD+ itself. It is the span of doses used across randomised human trials, not a titration schedule. A 2026 systematic review and meta-analysis of 15 parallel RCTs found NMN doses of 250-2000 mg/day for 14 days to 24 weeks. Within that, a dose-dependent RCT in 80 healthy middle-aged adults compared placebo, 300, 600 and 900 mg/day for 60 days, and found blood NAD+ raised at all doses and highest at 600 and 900 mg; a trial in 48 amateur runners used 300, 600 and 1200 mg/day for 6 weeks; and a phase 1/2 trial in immune thrombocytopenia used 450 mg twice daily for 2 weeks. Pooled analyses show good short-term tolerability but no significant effect on glucose control or lipids. Doses of the other common precursor, nicotinamide riboside, run higher still (2000-3000 mg/day) and are recorded in dosing_evidence_note rather than here, because NR is a third distinct molecule and folding it into this range would imply a ladder that does not exist. | Once daily (some trials split the dose twice daily) |
- IntermediateIntravenous
10 mg[1]
Once daily by intravenous infusion for 7 days
NAD+ itself, administered intravenously. The single largest randomised trial of NAD+ (not a precursor) in this corpus: 180 adults with ischemic cardiomyopathy, LVEF <=45%, NYHA II-III, randomised to intravenous NAD+ 10 mg/day or placebo (5% glucose/normal saline) for 7 days alongside guideline-directed therapy, with change in LVEF at 1 month as the primary endpoint. Two things follow. First, this is a 7-day inpatient course in heart failure, not a wellness protocol. Second, 10 mg/day is one to two orders of magnitude below the 500-1000 mg intravenous doses sold as NAD+ infusions, a gap the community figures do not acknowledge.
- IntermediateOral
Once daily (some trials split the dose twice daily)
THIS IS A DOSE OF beta-NICOTINAMIDE MONONUCLEOTIDE (NMN), a precursor, not of NAD+ itself. It is the span of doses used across randomised human trials, not a titration schedule. A 2026 systematic review and meta-analysis of 15 parallel RCTs found NMN doses of 250-2000 mg/day for 14 days to 24 weeks. Within that, a dose-dependent RCT in 80 healthy middle-aged adults compared placebo, 300, 600 and 900 mg/day for 60 days, and found blood NAD+ raised at all doses and highest at 600 and 900 mg; a trial in 48 amateur runners used 300, 600 and 1200 mg/day for 6 weeks; and a phase 1/2 trial in immune thrombocytopenia used 450 mg twice daily for 2 weeks. Pooled analyses show good short-term tolerability but no significant effect on glucose control or lipids. Doses of the other common precursor, nicotinamide riboside, run higher still (2000-3000 mg/day) and are recorded in dosing_evidence_note rather than here, because NR is a third distinct molecule and folding it into this range would imply a ladder that does not exist.
Published ranges, reported as the literature states them and numbered to the sources at the foot of this page. Not a recommendation.
evidence_level is recorded as limited_human rather than rct deliberately. Randomised trials do exist, but they are trials of the oral precursors (NR, NMN, nicotinamide, NADH) plus one intravenous NAD+ trial; the form this compound is actually bought and injected as (subcutaneous compounded NAD+) has no trial at any dose. Other human dosing figures found in the corpus that are NOT recorded as ranges because they belong to different molecules: nicotinamide riboside at 1000 mg twice daily for 12 weeks (PMID 29992272) and 1500 mg twice daily for 4 weeks, with the authors recommending phase II go to 3000 mg/day (PMID 38016950); and stabilised oral NADH (the reduced form) at 10 mg/day in chronic fatigue syndrome (PMID 10071523) and Alzheimer's disease (PMID 15134388).
NAD+ at a glance
- Category
- Longevity
- Half-life
- Not established
- Routes
- Oral, Subcutaneous, Other
- Regulatory status
- Not approved
- Also sold as
- NAD+, NAD, nicotinamide adenine dinucleotide, NMN, nicotinamide mononucleotide, NR, nicotinamide riboside, NAD+ precursor
Mechanism
NAD+ (nicotinamide adenine dinucleotide) is the central redox coenzyme of cellular metabolism, cycling between NAD+ and NADH to carry electrons through glycolysis, the TCA cycle and oxidative phosphorylation. It is also the obligatory substrate consumed by the sirtuin deacetylases, PARPs and CD38, which is why NAD+ is depleted rather than merely used, and why tissue NAD+ falls with age and with inflammatory or DNA-damage load. The longevity rationale is that restoring NAD+ restores sirtuin and mitochondrial function. Critically, most of the human work does not administer NAD+ at all: it administers a precursor, nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide or nicotinic acid, which is salvaged into NAD+ intracellularly. NR at 3000 mg/day raises whole-blood NAD+ up to 5-fold (PMID 38016950), and oral NMN at 300-900 mg/day raises blood NAD+ dose-dependently (PMID 36482258). NR, NMN and NAD+ are three distinct molecules and their doses are not interconvertible.
Reconstitution
Compounded injectable NAD+ is generally dispensed as a ready-made solution rather than a lyophilised powder, so no reconstitution is normally involved; where a powder is supplied, only the compounding pharmacy's own directions apply. Oral NMN and NR require no preparation.
Storage
There is no approved NAD+ product and therefore no label storage directions. Oral NMN and NR are sold as supplements and stored at room temperature. Compounded injectable NAD+ is dispensed by a compounding pharmacy, which sets its own storage and beyond-use dating. Follow the dispensing pharmacy's instructions, not a generic peptide storage rule.
Frequency in practice
Oral precursors are taken once daily (sometimes split twice daily). Injectable NAD+ is listed by clinics as one to three subcutaneous injections per week, or as an intravenous infusion per session.
Regulatory
No FDA-approved NAD+ drug product exists, and the openFDA label search returns no NAD+ label. Injectable NAD+ (subcutaneous or intravenous) is an unapproved compounded preparation dispensed by 503A/503B compounding pharmacies and administered off-label by wellness clinics. Oral NMN and NR are sold as dietary supplements. Clinical research on NAD+ repletion is active and substantial (25 registered trials in this packet alone), but it is overwhelmingly research on the oral precursors, not on injected NAD+.
What to know before anything else
ROUTE DEPENDENCE IS THE MAIN HAZARD HERE. Clinic and pharmacy listings for subcutaneous NAD+ cluster at 50-100 mg per injection, while intravenous listings from comparable operators run 500-1000 mg per session, roughly a 10x gap that is a route split, not a titration. A figure quoted without its route is actively dangerous, and the recorded community figure is subcutaneous only.
The only randomised trial of NAD+ itself in this corpus used 10 mg/day intravenously for 7 days in ischemic cardiomyopathy. That is 50-100x LOWER than the 500-1000 mg intravenous 'NAD+ drips' sold commercially. No trial in this corpus supports the commercial infusion doses.
No human trial in this corpus has studied SUBCUTANEOUS NAD+ at any dose. The 50-100 mg subcutaneous figure rests entirely on what compounding pharmacies and clinics advertise.
NAD+ precursors are not NAD+. NR at 2000-3000 mg/day and NMN at 250-2000 mg/day are oral doses of different molecules; neither tells you how much NAD+ to inject, and injected NAD+ dosing tells you nothing about oral precursor dosing.
Injectable NAD+ is compounded and unapproved: sterility, potency and purity rest entirely on the compounder, with none of the manufacturing controls behind an approved product.
Manage expectations from the trial record: meta-analyses of NMN RCTs (250-2000 mg/day, 8-15 trials) found no significant effect on fasting glucose, insulin, HbA1c, HOMA-IR or lipids, and a 12-week trial of NR 2000 mg/day in obese insulin-resistant men found no improvement in insulin sensitivity, hepatic lipid or energy expenditure.
High-dose NR (3000 mg/day for 4 weeks) produced a slight initial rise in serum homocysteine, although the methyl-donor pool remained intact. Short-term oral NMN up to 2000 mg/day has not shown increased adverse events or ALT/AST elevation in pooled RCT data, but no trial in this corpus runs beyond 24 weeks.
NAD+ questions
Is there an established human dose for NAD+?
Partly, and the detail matters more than the answer. The published range below covers two separate things: NAD+ itself given intravenously in a randomised trial of 180 people with ischaemic cardiomyopathy, and oral NMN across fifteen randomised trials. Neither is a wellness protocol, and neither is subcutaneous NAD+, which no published trial in this record has studied at any dose.
What is the difference between NAD+, NMN and NR?
NAD+ is the coenzyme itself, the molecule carrying electrons through glycolysis, the TCA cycle and oxidative phosphorylation, and the substrate that the sirtuin deacetylases, PARPs and CD38 consume rather than merely use. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors, salvaged into NAD+ intracellularly. Most of the human work does not administer NAD+ at all, it administers a precursor. They are three distinct molecules, their doses are not interconvertible, and a milligram figure for one says nothing about the other two. NR runs higher than NMN orally, which is why it is described in the evidence note rather than folded into the range table: a single ladder would imply a relationship that does not exist.
Is a subcutaneous NAD+ injection the same as an IV NAD+ drip?
No, and treating them as one thing is the main hazard with this compound. Clinic and pharmacy listings for subcutaneous NAD+ and for intravenous NAD+ differ by roughly ten times, which is a route split rather than a titration, so a figure quoted without its route is actively dangerous. The gap between the trial record and the market is wider still. The only randomised trial of NAD+ itself in this record used an intravenous dose roughly 50 to 100 times lower than the infusions sold commercially as NAD+ drips, over seven days, in hospitalised heart failure patients receiving guideline-directed therapy. No trial here supports the commercial infusion doses, and none covers the subcutaneous route at all.
Does NAD+ or NMN supplementation change anything measurable?
On metabolic endpoints the pooled trial record says no. A 2026 systematic review and meta-analysis of fifteen randomised trials of oral NMN found no effect on weight, BMI, fasting glucose, HbA1c, lipids or systolic blood pressure, with a small decrease in diastolic pressure and no increase in adverse events or liver enzymes. A 2024 meta-analysis of eight trials in 342 adults found no significant benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR or lipid profile. A 12-week trial of high-dose NR in obese insulin-resistant men found no improvement in insulin sensitivity, hepatic lipid or energy expenditure. What does move is the biomarker: a 2023 dose-ranging trial in 80 healthy middle-aged adults raised blood NAD+ at every dose tested. Raising NAD+ and changing an outcome are not the same finding.
Is injectable NAD+ approved?
No. No FDA-approved NAD+ drug product exists, and an FDA label search returns none. Injectable NAD+, subcutaneous or intravenous, is an unapproved compounded preparation dispensed by 503A and 503B compounding pharmacies and given off-label by wellness clinics. Sterility, potency and purity rest entirely on the compounder, with none of the manufacturing controls behind an approved product. Oral NMN and NR are sold as dietary supplements.
Does NAD+ need to be reconstituted, and how is it stored?
Usually there is nothing to reconstitute. Compounded injectable NAD+ is generally dispensed as a ready-made solution rather than a lyophilised powder, and where a powder is supplied only the compounding pharmacy's own directions apply. Storage works the same way: no approved product means no label storage directions, so the dispensing pharmacy sets storage and beyond-use dating, and that displaces any generic peptide storage rule you have read for other compounds. Oral NMN and NR need no preparation at all.
What does this record not tell you about NAD+?
Four gaps worth naming. It carries no half-life for NAD+, so the decay calculator has nothing to work from here. It records no reviewed interactions at all, which means nobody has assessed them for this library, not that none exist. No trial in it runs beyond 24 weeks, so long-term safety is unmeasured rather than reassuring. And high-dose oral NR produced a slight initial rise in serum homocysteine over four weeks, although the methyl-donor pool remained intact.
Every number above, and where it came from
4 sources, numbered where they are used. Each one links to the paper or the label itself, not to a summary of it.
- [1]Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial
American journal of cardiovascular drugs · 2026 · Randomized controlled trial · n=180
- [2]Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis
Nutrients · 2026 · Systematic review and meta-analysis
- [3]The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
GeroScience · 2023 · Randomized controlled trial (dose-ranging) · n=80
- [4]Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials
Current diabetes reports · 2024 · Systematic review and meta-analysis · n=342
The rest of the math
- Reconstitution calculatorThe full version of the tool above, with syringe barrel sizes and IU conversion.
- Vial longevityHow many doses a vial holds and the date it runs out.
- Cost per doseVial price against doses drawn, so two vial sizes can be compared honestly.
- Half-life and decayFirst-order clearance, time to steady state, and what remains at a given hour.
You worked out the draw. Now log this dose.
A calculator answers once and forgets. Dosavy keeps the concentration you mixed, the doses you actually took, and a reminder for the next one, with the same evidence labels you see on this page.